One Step Multi-Drug Screen Test Card

with the Integrated $iCup^{\mathbb{R}}$

Instruction Sheet for testing of any combination of the following drugs: AMP/BAR/BUP/BZO/COC/THC/MTD/mAMP/

MDMA/MOP/OPI/OXY/PCP/PPX/TCA

Available with Specimen Validity Tests (S.V.T.) for Oxidants/PCC, Specific Gravity, pH, Nitrite, Glutaraldehyde and Creatinine

A rapid, one step screening test for the simultaneous, gualitative detection of multiple drugs and drug metabolites in human urine

For healthcare professionals including professionals at point of care sites.

Immunoassay for in vitro diagnostic use only.

INTENDED USE

The **One Step Multi-Drug Screen Test Card with the Integrated** *i***Cup[®] is a lateral flow** chromatographic immunoassay for the qualitative detection of multiple drugs and drug metabolites in urine at the following cut-off concentrations:

| Test | Calibrator | Cut-off |
|--------------------------------------|-----------------------------------|-------------|
| Amphetamine (AMP 1,000) | d-Amphetamine | 1,000 ng/mL |
| Amphetamine (AMP 300) | d-Amphetamine | 300 ng/mL |
| Barbiturates (BAR) | Secobarbital | 300 ng/mL |
| Benzodiazepines (BZO) | Oxazepam | 300 ng/mL |
| Buprenorphine (BUP) | Buprenorphine | 10 ng/mL |
| Cocaine (COC 300) | Benzoylecgonine | 300 ng/mL |
| Cocaine (COC 150) | Benzoylecgonine | 150 ng/mL |
| Marijuana (THC) | 11-nor-Δ ⁹ -THC-9 COOH | 50 ng/mL |
| Methadone (MTD) | Methadone | 300 ng/mL |
| Methamphetamine (mAMP 1,000) | d-Methamphetamine | 1,000 ng/mL |
| Methamphetamine (mAMP 500) | d-Methamphetamine | 500 ng/mL |
| Methylenedioxymethamphetamine (MDMA) | d,I-Methylenedioxymethamphetamine | 500 ng/mL |
| Opiate (MOP 300) | Morphine | 300 ng/mL |
| Opiate (OPI 2,000) | Morphine | 2,000 ng/mL |
| Oxycodone (OXY) | Oxycodone | 100 ng/mL |
| Phencyclidine (PCP) | Phencyclidine | 25 ng/mL |
| Propoxyphene (PPX) | Propoxyphene | 300 ng/mL |
| Tricyclic Antidepressants (TCA) | Nortriptyline | 1,000 ng/mL |

Configurations of the One Step Multi-Drug Screen Test Card with the Integrated iCup® come with any combination of the above listed drug analytes. This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are

SUMMARY

The One Step Multi-Drug Screen Test Card with the Integrated iCup® is a rapid urine screen test that can be performed without the use of an instrument. The test utilizes monoclonal antibodies to selectively detect elevated levels of specific drugs in urine.

AMPHETAMINE (AMP 1,000)

Amphetamine is a Schedule II controlled substance available by prescription (Dexedrine[®]) and is also available on the illicit market. Amphetamines are a class of potent sympathomimetic agents with therapeutic applications. They are chemically related to the human body's natural catecholamines: epinephrine and norepinephrine. Acute higher doses lead to enhanced stimulation of the central nervous system (CNS) and induce euphoria, alertness, reduced appetite, and a sense of increased energy and power. Cardiovascular responses to amphetamines include increased blood pressure and cardiac arrhythmias. More acute responses produce anxiety, paranoia, hallucinations, and psychotic behavior. The effects of Amphetamines generally last 2-4 hours following use and the drug has a half-life of 4-24 hours in the body. About 30% of amphetamines are excreted in the urine in unchanged form, with the remainder as hydroxylated and deaminated derivatives.

The One Step Multi-Drug Screen Test Card with the Integrated /Cup® yields a positive result when the concentration of amphetamines in urine exceeds 1,000 ng/mL.

AMPHETAMINE (AMP 300)

The One Step Multi-Drug Screen Test Card with the Integrated *i*Cup[®] yields a positive result when amphetamines in urine exceed 300 ng/mL. See AMPHETAMINE (AMP 1,000) for the summary.

BARBITURATES (BAR)

Barbiturates are CNS depressants. They are used therapeutically as sedatives, hypnotics, and anticonvulsants. Barbiturates are almost always taken orally as capsules or tablets. The effects resemble those of intoxication with alcohol. Chronic use of barbiturates leads to tolerance and physical dependence. Short-acting barbiturates taken at 400 mg/day for 2-3 months can produce a clinically significant degree of physical dependence. Withdrawal symptoms experienced during periods of drug inence can be severe enough to cause death

Only a small amount (less than 5%) of most barbiturates are excreted unaltered in the urine.

| The approximate detection time lin | nits for barbiturates are: |
|------------------------------------|----------------------------|
| Short acting (e.g. Secobarbital) | 100 mg PO (oral) |

4.5 days Long acting (e.g. Phenobarbital) 400 mg PO (oral) 7 davs² The One Step Multi-Drug Screen Test Card with the Integrated iCup® yields a positive result when the concentration of barbiturates in urine exceeds 300 ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cutoff for Barbiturate positive specimens

BENZODIAZEPINES (BZO)

Benzodiazepines are medications that are frequently prescribed for the symptomatic treatment of anxiety and sleep disorders. They produce their effects via specific receptors involving a neurochemical called gamma aminobutyric acid (GABA). Because they are safer and more effective, benzodiazepines have replaced barbiturates in the treatment of both anxiety and insomnia Benzodiazepines are also used as sedatives before some surgical and medical procedures, and for the treatment of seizure disorders and alcohol withdrawal.

Risk of physical dependence increases if benzodiazepines are taken regularly (e.g., daily) for more than a few months, especially at higher than normal doses. Stopping abruptly can bring on such symptoms as trouble sleeping, gastrointestinal upset, feeling unwell, loss of appetite, sweating, trembling, weakness, anxiety and changes in perception.

Only trace amounts (less than 1%) of most benzodiazepines are excreted unaltered in the urine; most of the

concentration in urine is conjugated drug. The detection period for benzodiazepines in urine is 3-7 days. The **One Step Multi-Drug Screen Test Card with the Integrated iCup**[®] yields a positive result when the concentration of benzodiazepines in urine exceeds 300 ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cutoff for benzodiazepine positive specimens.

BUPRENORPHINE (BUP)

Buprenorphine is a potent analgesic often used in the treatment of opioid addiction. The drug is sold under the trade names Subutex[™], Buprenex[™], Temgesic[™] and Suboxone[™], which contain Buprenorphine HCl alone or in combination with Naloxone HCl. Therapeutically, Buprenorphine is used as a substitution treatment for opioid addicts. Substitution treatment is a form of medical care offered to opiate addicts (primarily heroin addicts) based on a similar or identical substance to the

drug normally used. In substitution therapy, Buprenorphine is as effective as Methadone but monstrates a lower level of physical dependence. Concentrations of free Buprenorphine and Norbuprenorphine in urine may be less than 1 ng/ml after therapeutic administration, but can range up to 20 ng/ml in abuse situations.³ The plasma half life of Buprenorphine is 2-4 hours.³ While complete elimination of a single dose of the drug can take as long as 6 days, the window of detection for the parent drug in urine is thought to be approximately 3 days.

Substantial abuse of Buprenorphine has also been reported in many countries where various forms of the drug are available. The drug has been diverted from legitimate channels through theft, doctor shopping, and fraudulent prescriptions, and been abused via intravenous, sublingual, intranasal and

The One Step Multi-Drug Screen Test Card with the Integrated iCup® yields a positive result when the concentration of Buprenorphine in urine exceeds 10 ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for buprenorphine positive specimens.

COCAINE (COC 300)

Cocaine is a potent central nervous system stimulant and a local anesthetic. Initially, it brings about extreme energy and restlessness while gradually resulting in tremors, over-sensitivity and spasms. In large amounts, cocaine causes fever, unresponsiveness, difficulty in breathing and unconsciousness. Cocaine is often self-administered by nasal inhalation, intravenous injection and free-base smoking. It is excreted in the urine in a short time primarily as benzoylecgonine.^{4,5} Benzoylecgonine, a major metabolite of cocaine, has a longer biological half-life (5-8 hours) than cocaine (0.5-1.5 hours), and can generally be detected for 24-48 hours after cocaine exposure

The One Step Multi-Drug Screen Test Card with the Integrated *i*Cup[®] yields a positive result when the concentration of benzoylecgonine in urine exceeds 300 ng/ml

COCAINE (COC 150)

The One Step Multi-Drug Screen Test Card with the Integrated *i*Cup[®] yields a positive result when the concentration of benzoylecgonine in urine exceeds 150 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).1 See COCAINÉ (COC 300) for the summary

MARIJUANA (THC)

THC (Δ^9 -tetrahydrocannabinol) is the primary active ingredient in cannabis (marijuana). When smoked or orally administered, THC produces euphoric effects. Users have impaired short-term memory and slowed learning. They may also experience transient episodes of confusion and anxiety. Long-term, relatively heavy use may be associated with behavioral disorders. The peak effect of marijuana administered by smoking occurs in 20-30 minutes and the duration is 90-120 minutes after one cigarette. Elevated levels of urinary metabolites are found within hours of exposure and remain detectable for 3-10 days after smoking. The main metabolite excreted in the urine is $11-nor-\Delta^9$ tetrahydrocannabinol-9-carboxylic acid (THC-COOH).

The One Step Multi-Drug Screen Test Card with the Integrated iCup® yields a positive result when the concentration of THC-COOH in urine exceeds 50 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).¹

METHADONE (MTD)

Methadone is a narcotic analgesic prescribed for the management of moderate to severe pain and for the treatment of opiate dependence (heroin, Vicodin, Percocet, morphine). The pharmacology of oral methadone is very different from IV methadone. Oral methadone is partially stored in the liver for later use. IV methadone acts more like heroin. In most states you must go to a pain clinic or a methadone maintenance clinic to be prescribed methadone.

Methadone is a long acting pain reliever producing effects that last from twelve to forty-eight hours. Ideally, methadone frees the client from the pressures of obtaining illegal heroin, from the dangers of injection, and from the emotional roller coaster that most opiates produce. Methadone, if taken for long periods and at large doses, can lead to a very long withdrawal period. The withdrawals from methadone are more prolonged and troublesome than those provoked by heroin cessation, yet the substitution and phased removal of methadone is an acceptable method of detoxification for patients and therapists.²

The One Step Multi-Drug Screen Test Card with the Integrated *i*Cup[®] yields a positive result when the concentration of methadone in urine exceeds 300 ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for methadone positive specimens

METHAMPHETAMINE (mAMP 1.000)

Methamphetamine is an addictive stimulant drug that strongly activates certain systems in the brain. Methamphetamine is closely related chemically to amphetamine, but the CNS effects of methamphetamine are greater. Methamphetamine is made in illegal laboratories and has a high potential for abuse and dependence. The drug can be taken orally, injected, or inhaled. Acute higher doses lead to enhanced stimulation of the CNS and induce euphoria, alertness, reduced appetite and a sense of increased energy and power. Cardiovascular responses to methamphetamine include increased blood pressure and cardiac arrhythmias. More acute responses produce anxiety, paranoia hallucinations, psychotic behavior, and eventually, depression and exhaustion.

The effects of methamphetamine generally last 2-4 hours and the drug has a half-life of 9-24 hours in the body. Methamphetamine is excreted in the urine as amphetamine and oxidized and deaminated derivatives. However, 10-20% of methamphetamine is excreted unchanged. Thus, the presence of the parent compound in the urine indicates methamphetamine use. Methamphetamine is generally detectable in the urine for 3-5 days, depending on urine pH level. The One Step Multi-Drug Screen Test Card with the Integrated *i*Cup[®] yields a positive result

when the concentration of methamphetamine in urine exceeds 1,000 ng/mL. This is the historical screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).

METHAMPHETAMINE (mAMP 500)

The One Step Multi-Drug Screen Test Card with the Integrated *i*Cup[®] yields a positive result when the concentration of methamphetamine in urine exceeds 500 ng/mL. See METHAMPHETAMINE (mAMP 1,000) for the summary

METHYLENEDIOXYMETHAMPHETAMINE (MDMA)

Methylenedioxymethamphetamine (ecstasy) is a designer drug first synthesized in 1914 by a German drug company for the treatment of obesity.⁶ Those who take the drug frequently report adverse effects, such as increased muscle tension and sweating. MDMA is not clearly a stimulant, although it has, in common with amphetamine drugs, a capacity to increase blood pressure and heart rate. MDMA does produce some perceptual changes in the form of increased sensitivity to light, difficulty in focusing, and blurred vision in some users. Its mechanism of action is thought to be via release of the neurotransmitter serotonin. MDMA may also release dopamine, although the general opinion is that this is a secondary effect of the drug (Nichols and Oberlender, 1990). The most pervasive effect of MDMA, occurring in virtually all people who took a reasonable dose of the drug, was to produce a clenching of the jaws

The One Step Multi-Drug Screen Test Card with the Integrated *i*Cup[®] yields a positive result when the concentration of Methylenedioxymethamphetamine in urine exceeds 500 ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for Methylenedioxymethamphetamine positive specimens OPIATE (MOP 300)

Opiate refers to any drug that is derived from the opium poppy, including the natural products, morphine and codeine, and the semi-synthetic drugs such as heroin. Opioid is more general, referring to any drug that acts on the opioid receptor. Opioid analgesics comprise a large group of substances which control pain by depressing the CNS.

Large doses of morphine can produce higher tolerance levels, physiological dependency in users, and may lead to substance abuse. Morphine is excreted unmetabolized, and is also the major metabolic product of codeine and heroin. Morphine is detectable in the urine for several days after an opiate dose

The One Step Multi-Drug Screen Test Card with the Integrated iCup® yields a positive result when the concentration of morphine in urine exceeds 300 ng/mL

OPIATE (OPI 2,000)

The One Step Multi-Drug Screen Test Card with the Integrated /Cup® vields a positive result when the concentration of morphine in urine exceeds 2,000 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).1 See OPIATE (MOP 300) for summary.

Oxycodone is a semi-synthetic opioid with a structural similarity to codeine. The drug is manufactured by modifying thebaine, an alkaloid found in the opium poppy. Oxycodone, like all opiate agonists, provides pain relief by acting on opioid receptors in the spinal cord, brain, and possibly directly in the affected tissues. Oxycodone is prescribed for the relief of moderate to high pain under the well-known pharmaceutical trade names of OxyContin®, Tylox®, Percodan® and Percocet®. While Tylox, Percodan and Percocet contain only small doses of oxycodone hydrochloride combined with other analgesics such as acetaminophen or aspirin, OxyContin consists solely of oxycodone hydrochloride in a time-release form.

Oxycodone is known to metabolize by demethylation into oxymorphone and noroxycodone. In a 24hour urine, 33-61% of a single, 5 mg oral dose is excreted with the primary constituents being unchanged drug (13-19%), conjugated drug (7-29%) and conjugated oxymorphone (13-14%).² The window of detection for oxycodone in urine is expected to be similar to that of other opioids such as

The One Step Multi-Drug Screen Test Card with the Integrated *i*Cup[®] yields a positive result when the concentration of oxycodone in urine exceeds 100 ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for oxycodone positive specimens

PHENCYCLIDINE (PCP)

Phencyclidine, also known as PCP or Angel Dust, is a hallucinogen that was first marketed as a surgical anesthetic in the 1950's. It was removed from the market because patients receiving it became delirious and experienced hallucinations.

PCP is used in powder, capsule, and tablet form. The powder is either snorted or smoked after mixing it with marijuana or vegetable matter. PCP is most commonly administered by inhalation but can be used intravenously, intra-nasally, and orally. After low doses, the user thinks and acts swiftly and experiences mood swings from euphoria to depression. Self-injurious behavior is one of the astating effects of PCP.

PCP can be found in urine within 4 to 6 hours after use and will remain in urine for 7 to 14 days depending on factors such as metabolic rate, user's age, weight, activity, and diet.⁷ PCP is excreted

in the urine as an unchanged drug (4% to 19%) and conjugated metabolites (25% to 30%).⁸ The **One Step Multi-Drug Screen Test Card with the Integrated** i**Cup**[®] yields a positive result when the concentration of phencyclidine in urine exceeds 25 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).

PROPOXYPHENE (PPX)

Propoxyphene (PPX) is a narcotic analoesic compound bearing structural similarity to methadone. As an analgesic, propoxyphene can be from 50-75% as potent as oral codeine. Darvocet™, one of the most common brand names for the drug, contains 50-100 mg of propoxyphene napsylate and 325-650 mg of acetaminophen. Peak plasma concentrations of propoxyphene are achieved from 1 to 2 hours post dose. In the case of overdose, proposyphene blood concentrations can reach significantly higher levels.

In humans, proposyphene is metabolized by N-demethylation to yield norproposyphene Norpropoxyphene has a longer half-life (30 to 36 hours) than parent propoxyphene (6 to 12 hours). The accumulation of norproposyphene seen with repeated doses may be largely responsible for

The One Step Multi-Drug Screen Test Card with the Integrated *i*Cup[®] yields a positive result when the concentration of Propoxyphene or Norpropoxyphene in urine exceeds 300 ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for propoxyphene positive specimens.

TRICYCLIC ANTIDEPRESSANTS (TCA)

TCA (Tricyclic Antidepressants) are commonly used for the treatment of depressive disorders. TCA overdoses can result in profound CNS depression, cardiotoxicity and anticholinergic effects, TCA overdose is the most common cause of death from prescription drugs. TCAs are taken orally or sometimes by injection. TCAs are metabolized in the liver. Both TCAs and their metabolites are excreted in urine mostly in the form of metabolites for up to ten days.

The One Step Multi-Drug Screen Test Card with the Integrated iCup® yields a positive result when the concentration of tricyclic antidepressants in urine exceeds 1,000 ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for tricyclic antidepressant positive specimens.

S.V.T. SUMMARY

(Information regarding Specimen Validity Tests does not require FDA review.) The strip contains chemically treated reagent pads. 3-5 minutes following the activation of the reagent pads by the urine sample, the colors that appear on the pads can be compared with the printed color chart card. The color comparison provides a semi-quantitative screen for any combination of oxidants/pyridinium chlorochromate (PCC), specific gravity, pH, nitrite, glutaraldehyde and creatinine in human urine which can help assess the integrity of the urine sample

WHAT IS ADULTERATION?

Adulteration is the tampering of a urine specimen with the intention of altering the test results. use of adulterants can cause false negative results in drug tests by either interfering with the screening test and/or destroying the drugs present in the urine. Dilution may also be employed in an attempt to produce false negative drug test results. One of the best ways to test for adulteration or dilution is to determine certain urinary characteristics

such as pH and specific gravity and to detect the presence of oxidants/PCC, specific gravity, pH. nitrite, glutaraldehyde and creatinine in urine.

- · Oxidants/PCC (Pyridinium chlorochromate) tests for the presence of oxidizing agents such as bleach and hydrogen peroxide. Pyridinium chlorochromate (sold under the brand name UrineLuck) is a commonly used adulterant ⁸ Normal human urine should not contain oxidants or PCC
- Specific gravity tests for sample dilution. The normal range is from 1.003 to 1.030. Values outside this range may be the result of specimen dilution or adulteration. pH tests for the presence of acidic or alkaline adulterants in urine. Normal pH levels should be in
- The range of 4.0 to 9.0. Values outside of this range may indicate the sample has been altered. **Nitrite** tests for commonly used commercial adulterants such as Klear or Whizzies. They work by oxidizing the major cannabinoid metabolite THC-COOH.⁹ Normal urine should contain no trace of nitrite. Preliminary positive results generally indicate the presence of an adulterant.
- Glutaraldehyde tests for the presence of an aldehyde. Adulterants such as UrinAid and Clear Choice contain glutaraldehyde which may cause false negative screening results by disrupting the enzyme used in some immunoassay tests.⁸ Glutaraldehyde is not normally found in urine; therefore, detection of glutaraldehyde in a urine specimen is generally an indicator of adulteration.
- Creatinine is a waste product of creatine; an amino-acid contained in muscle tissue and found in urine.² A person may attempt to foil a test by drinking excessive amounts of water or diuretics such as herbal teas to "flush" the system. Creatinine and specific gravity are two ways to check for dilution and flushing, which are the most common mechanisms used in an attempt to circumvent drug testing. Low creatinine and specific gravity levels may indicate dilute urine. The absence of creatinine (< 5 mg/dl) is indicative of a specimen not consistent with human urine

PRINCIPLE

The One Step Multi-Drug Screen Test Card with the Integrated *i*Cup[®] is an immunoassay based on the principle of competitive binding. Drugs which may be present in the urine specimen compete against their respective drug conjugate for binding sites on their specific antibody. During testing, a urine specimen migrates upward by capillary action. A drug, if present in the urine

specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test region of the specific drug strip. The presence of drug above the cut-off concentration will saturate all the binding sites of the antibody. Therefore, the colored line will not form in the test region. A drug-positive urine specimen will not generate a colored line in the specific test region of the strip

because of drug competition, while a drug-negative urine specimen will generate a line in the test region because of the absence of drug competition.

To serve as a procedural control, a colored line will always appear at the control region, indicating that proper volume of specimen has been added and membrane wicking has occurred REAGENTS

Each test contains anti-drug mouse monoclonal antibody and corresponding drug-protein conjugates The control line contains goat anti-rabbit IgG polyclonal antibodies and rabbit IgG.

| S.V.II. REAGENTS | | | | | | | | | |
|------------------|--------------------|--------------------------------------|---|--|--|--|--|--|--|
| Adulteration Pad | Reactive indicator | Buffers and non-reactive ingredients | 1 | | | | | | |
| Oxidants/PCC | 0.36% | 99.64% | | | | | | | |
| Specific Gravity | 0.25% | 99.75% | | | | | | | |
| pH | 0.06% | 99.94% | 1 | | | | | | |
| Nitrite | 0.07% | 99.93% | | | | | | | |
| Glutaraldehyde | 0.02% | 99.98% | | | | | | | |
| Creatinine | 0.04% | 99.96% | | | | | | | |
| | PRECAUTIO | NS | | | | | | | |

SVT REAGENTS

- For healthcare professionals including professionals at point of care sites. Immunoassay for *in vitro* diagnostic use only. Do not use after the expiration date
- The test cup should remain in the sealed pouch until use.
- All specimens should be considered potentially hazardous and handled in the same manner as an
- infectious agent.
- The used test cup should be discarded according to federal, state and local regulations

STORAGE AND STABILITY

Store as packaged in the sealed pouch at 2-30°C (36-86°F). The test is stable through the expiration date printed on the sealed pouch. The test devices must remain in the sealed pouch until use. DO date printed on the sealed pouch. The test devices minor FREEZE. Do not use beyond the expiration date. SPECIMEN COLLECTION AND PREPARATION

Urine Assay

The urine specimen must be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be centrifuged, filtered, or allowed to settle to obtain a clear specimen for testing.

Specimen Storage

Urine specimens may be stored at 2-8°C for up to 48 hours prior to testing. For prolonged storage, specimens may be frozen and stored below -20°C. Frozen specimens should be thawed and mixed well before testing. When tests include S.V.T., storage of urine specimens should not exceed 2 hours at room temperature or 4 hours refrigerated prior to testing. For best results, test specime ediately following collection.

MATERIALS Materials Provided


- · Cups with multi-drug panels [Note: A Fahrenheit temperature strip is affixed to aid in the determination of specimen validity. Please use this temperature strip in conjunction with your Drug Free Policy (if applicable)]. Adulteration color chart (if applicable)
- Security seal label
- Package insert
- Procedure card

Date

- Materials Required But Not Provided
- A timer or any kind of a timing device such as a wrist red to run this test
- External controls

DIRECTIONS FOR USE

- Allow the test cup, urine specimen, and/or controls to equilibrate to room temperature (1 30°C) prior to testing ig the pouch to room temperature before opening it. Remove the cup from the sealed pouch
- and use it as soon as possible.
- Donor provides specimen.
- Technician replaces and secures cap while the cup is on a flat surface Donor dates and initials the security seal and attaches the security seal over the cup cap.
- Technician peels off the label to view results.
- The adulteration strip(s), if applicable, should be read between 3-5 minutes. Compare the colors on the dulteration strip to the color chart. If the results indicate adulteration, do not read the drug test res 7. If results do not indicate adulteration, read the drug test result at 5 minutes. The drug test results
- If preliminary positive results are observed, please send the cup to the laboratory for confirmation.



INTERPRETATION OF RESULTS

NEGATIVE:* A colored line appears in the Control region (C) and a colored line appears in the Test region (Drug/T) next to a specific drug tested. This negative result means that the drug concentrations in the urine sample are below the designated cut-off levels for a particular drug tested. *NOTE: The shade of the colored line(s) in the Test region may vary. The result should be considered negative whenever there is even a faint colored line.

POSITIVE: A colored line appears in the Control region (C) and NO line appears in the Test region (Drug/T) next to the name of a specific drug tested. The positive result means that the drug concentration in the urine sample is greater than the designated cut-off for a specific drug. INVALID: No line appears in the Control region (C). Insufficient specimen volume or incorrect

procedural techniques are the most likely reasons for control line failure. Read the directions again and repeat the test with a new test cup. If the result is still invalid, contact your manufacturer.

SVT/ADULTERANT INTERPRETATION (Please refer to the color chart)

Semi-quantitative results are obtained by visually comparing the reacted color blocks on the adulteration strips to the printed color blocks on the color chart. No instrumentation is required.

QUALITY CONTROL

A procedural control is included in the test. A line appearing in the Control region (C) is considered ar internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

Control standards are not supplied with this kit. However, it is recommended that positive and negative controls be tested as good laboratory practice to confirm the test procedure and to verify , per test performance

LIMITATIONS

- 1. The One Step Multi-Drug Screen Test Card with the Integrated iCup® provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method
- 2. There is a possibility that technical or procedural errors, as well as interfering substances in the a rine specimen may cause erroneous results.
 Adulterants, such as bleach and/or alum, in urine specimens may produce erroneous results.
- regardless of the analytical method used. If adulteration is suspected, the test should be repeated with another urine specimen.
- 4. A positive result does not indicate level or intoxication, administration route or concentration in urine 5. A negative result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the cut-off level of the test.
- 6. This test does not distinguish between drugs of abuse and certain medications.
- 7. A positive test result may be obtained from certain foods or food supplements

S.V.T. ADULTERATION LIMITATIONS

. The adulteration tests, included with this product, are meant to aid in the determination of abnormal specimens. While comprehensive, these tests are not meant to be an all-inclusive representation of possible adulterants.

- 2. Oxidants/PCC: Normal human urine should not contain oxidants or PCC. The presence of high evels of antioxidants in the specimen, such as ascorbic acid, may result in false negative for the oxidants/PCC pad.
- Specific Gravity: Elevated levels of protein in urine may cause abnormally high specific gravity values.
 Nitrite: Nitrite is not a normal component of human urine. However, nitrite found in urine may indicate urinary tract infections or bacterial infections. Nitrite levels of > 20 mg/dL may produce
- false preliminary positive glutaraldehyde results. 5. Glutaraldehyde: Is not normally found in urine. However certain metabolic abnormalities such as ketoacidosis (fasting, uncontrolled diabetes or high-protein diets) may interfere with the test results.
- 6. Creatinine: Normal creatinine levels are between 20 and 350 mg/dL. Under rare conditions, certain kidney diseases may show dilute urine.

PERFORMANCE CHARACTERISTICS

Accuracy

A side-by-side comparison was conducted using the **One Step Multi-Drug Screen Test Card with the Integrated** *i***Cup**[®] and commercially available drug rapid tests. Testing was performed on approximately 300 positive results were confirmed by GC/MS. The following compounds were quantified by GC/MS and contributed to the total amount of drugs found in presumptive positive urine samples tested.

| Test | Compounds Contributing to GC/MS Totals |
|------|--|
| AMP | Amphetamine |
| BAR | Secobarbital, Butalbital, Phenobarbital, Pentobarbital |
| BUP | Buprenorphine |
| BZO | Oxazepam, Nordiazepam, α-Hydroxyalprazolam, Desalkylflurazepam |
| COC | Benzoylecgonine |
| THC | 11-nor-∆9-tetrahydrocannabinol-9-carboxylic acid |
| MTD | Methadone |
| mAMP | Methamphetamine |
| MDMA | d,I-Methylenedioxymethamphetamine |
| OPI | Morphine, Codeine |
| OXY | Oxycodone |
| PCP | Phencyclidine |
| PPX | Propoxyphene |
| TCA | Nortriptyline |

The following results are tabulated from these clinical studies:

% Agreement with Commercial Kit

| | Method | | Predicate 1 | est Results | % Agreement with |
|---------------------------|-------------|----------|-------------|-------------|------------------|
| | Method | | Positive | Negative | Predicate Test |
| | AMP 1,000 | Positive | 129 | 0 | >99% |
| | AIVIP 1,000 | Negative | 0 | 172 | >99% |
| | AMP 300 | Positive | 127 | 0 | >99% |
| | AIVIE 300 | Negative | 0 | 173 | >99% |
| | BAR | Positive | 126 | 1 | >99% |
| | DAR | Negative | 0 | 165 | 99% |
| | BUP | Positive | * | * | * |
| | DUP | Negative | * | * | * |
| | BZO | Positive | 131 | 0 | >99% |
| | BZU | Negative | 1 | 162 | >99% |
| | COC 300 | Positive | 112 | 1 | >99% |
| | | Negative | 0 | 186 | 99% |
| | COC 150 | Positive | 141 | 0 | >99% |
| | | Negative | 0 | 159 | >99% |
| | mAMP 1,000 | Positive | 121 | 0 | 99% |
| | | Negative | 1 | 174 | >99% |
| | mAMP 500 | Positive | 108 | 39** | >99% |
| One Step Multi- | | Negative | 0 | 153 | 80% |
| Drug Screen | MDMA | Positive | 86 | 0 | >95% |
| Test Card with | IVIDIVIA | Negative | 4 | 152 | >99% |
| the Integrated | MOP | Positive | 125 | 0 | 95% |
| <i>i</i> Cup [®] | MOP | Negative | 7 | 150 | >99% |
| roup | MTD | Positive | 120 | 0 | 87% |
| | WID | Negative | 18 | 168 | >99% |
| | 0.01 | Positive | 131 | 0 | 98% |
| | OPI | Negative | 2 | 164 | >99% |
| | 0)/// | Positive | 135 | 1 | 96% |
| | OXY | Negative | 5 | 159 | 99% |
| | DOD | Positive | 71 | 0 | 99% |
| | PCP | Negative | 1 | 160 | >99% |
| | DDV | Positive | 157 | 0 | >99% |
| | PPX | Negative | 0 | 157 | >99% |
| | TOA | Positive | 45 | 0 | 92% |
| | TCA | Negative | 4 | 177 | >99% |
| | THO | Positive | 124 | 1 | >99% |
| | THC | Negative | 0 | 175 | 99% |

Commercial kit unavailable for BUP * 32 specimens showed >500 ng/mL concentration by GC/MS

% Agreement with GC/MS

| | | | % Agree | ement with GC | J/MS | | |
|-----------|--|------|----------------------------|--|--|----------------------------|---------------------------------|
| M | ethod | | | G | C/MS | | |
| Screen Te | o Multi-Drug est Card with rated <i>i</i> Cup® | Neg. | Neg. (< –25% cutoff) | Near cutoff neg. (-25% cutoff to cutoff) | Near cutoff pos. (cutoff to +25% cutoff) | Pos. (> +25% cutoff) | % agreement with GC/MS |
| AMP | Positive | 0 | 1 | 8 | 18 | 114 | 97% |
| 1,000 | Negative | 149 | 1 | 5 | 4 | 0 | 95% |
| BAR | Positive | 0 | 0 | 4 | 5 | 117 | 92% |
| DAR | Negative | 150 | 1 | 5 | 1 | 9 | 98% |
| BZO | Positive | 0 | 7 | 1 | 5 | 26 | 97% |
| BZO | Negative | 149 | 7 | 1 | 3 | 1 | 95% |
| COC | Positive | 0 | 2 | 15 | 16 | 103 | 98% |
| 300 | Negative | 150 | 5 | 7 | 1 | 1 | 90% |
| THC | Positive | 0 | 6 | 3 | 12 | 104 | 95% |
| IIIC | Negative | 150 | 13 | 6 | 2 | 4 | 95% |
| MTD | Positive | 0 | 0 | 10 | 10 | 112 | 99% |
| IVITD | Negative | 150 | 17 | 0 | 0 | 1 | 94% |
| mAMP | Positive | 0 | 0 | 10 | 9 | 126 | 99% |
| 1,000 | Negative | 150 | 0 | 4 | 1 | 0 | 94% |
| MDMA | Positive | 0 | 0 | 3 | 6 | 82 | >99% |
| IVIDIVIA | Negative | 147 | 0 | 2 | 0 | 0 | 98% |
| MOP | Positive | 0 | 2 | 7 | 10 | 131 | >99% |
| WOI | Negative | 150 | 0 | 0 | 0 | 0 | 94% |
| OPI | Positive | 0 | 0 | 16 | 18 | 116 | >99% |
| 011 | Negative | 150 | 0 | 0 | 0 | 0 | 90% |
| PCP | Positive | 0 | 0 | 6 | 10 | 40 | >99% |
| 1.01 | Negative | 150 | 6 | 0 | 0 | 0 | 96% |
| *TCA | Positive | 0 | 12 | 8 | 15 | 20 | >99% |
| ICA | Negative | 150 | 17 | 0 | 0 | 0 | 89% |

* When compared with HP/LC at a cut-off of 1.000ng/ml, the following results were tabulated

| M | lethod | | GC/MS | | | | | | | | |
|-------------|---|----------|----------------------------|--|--|----------------------------|------------------------------|--|--|--|--|
| Screen T | p Multi-Drug est Card with grated <i>i</i> Cup [®] | Neg. | Neg. (< –25% cutoff) | Near cutoff neg. (-25% cutoff to cutoff) | Near cutoff pos. (cutoff to +25% cutoff) | Pos. (> +25% cutoff) | % agreement with GC/MS | | | | |
| *BUP | Positive | 0 | 0 | 0 | 5 | 50 | 98% | | | | |
| BUP | Negative | 150 | 15 | 5 | 1 | 0 | >99% | | | | |
| PPX | Positive | 0 | 0 | 2 | 7 | 158 | 94% | | | | |
| FFA | Negative | 152 | 5 | 18 | 10 | 0 | 99% | | | | |
| AMP | Positive | 0 | 1 | 1 | 2 | 123 | 99% | | | | |
| 300 | Negative | 150 | 18 | 5 | 0 | 0 | 99% | | | | |
| OXY | Positive | 0 | 0 | 1 | 2 | 133 | 98% | | | | |
| UXY | Negative | 147 | 6 | 8 | 0 | 3 | 99% | | | | |
| legative sa | mples were o | onfirmed | negative us | sing LC/MS by p | ooling these san | nples into g | roups of 15. | | | | |
| | Method | | | | GC/MS | | | | | | |

| M | ethoo | 4 | | | | GC/M | S | | | |
|----------------------------------|--------|-------------|-------------------------|-------|----------------------------------|----------------------------------|------|----------------------------|---|------------------------------|
| One Ste Screen Tes Integra | st Car | rd with the | Neg. | (-25% | utoff neg. cutoff to toff) | Near cuto (cutoff to cutof | +25% | Pos. (> +25% cutoff) | 5 | % agreement with GC/MS |
| COC | F | Positive | 0 | | 0 | 10 | | 131 | | >99% |
| 150 | N | legative | 150 | | 7 | 0 | | 2 | | 98% |
| | | | Method | | | GC/N | IS | | 1 | |
| | | | Multi-Drug Card with | the | Neg. | Pos. | | reement GC/MS | | |

Negative 153 0 500 Forty (40) clinical samples for each drug were run using each of the **One Step Multi-Drug Screen Test Card with the Integrated iCup**[®] by an untrained operator at a professional point of care site. Based on GC/MS data, the operator obtained statistically similar positive agreement, negative agreement and overall agreement rates as trained laboratory personnel.

Positive

mAMF

Precision

7 140

>99%

96%

A study was conducted at three physician offices for Amphetamine (1,000 ng/mL), Cocaine (300 ng/mL), Marijuana, Methamphetamine (1,000 ng/mL), Opiate and Phencyclidine by untrained operators using three different lots of product to demonstrate the within run, between run and between operator precision. An identical panel of coded specimens, containing drugs at the concentration of \pm 50% and \pm 25% cut-off level, was labeled as a blind and tested at each site. The results are given below:

| Dava Gana | n | Sit | e A | Sit | e B | Sit | e C |
|--------------|----------|-----|-----|-----|-----|-----|-----|
| Drug Conc. | per site | - | + | - | + | - | + |
| Negative | 90 | 90 | 0 | 90 | 0 | 90 | 0 |
| -50% Cut-off | 90 | 90 | 0 | 88 | 2 | 89 | 1 |
| -25% Cut-off | 90 | 80 | 10 | 70 | 20 | 70 | 20 |
| +25% Cut-off | 90 | 34 | 56 | 13 | 77 | 12 | 78 |
| +50% Cut-off | 90 | 5 | 85 | 5 | 85 | 3 | 87 |

A study was conducted at three physician offices for Barbiturates Benzodiazenines. Methadone Methylenedioxymethamphetamine, Morphine, and Tricyclic Antidepressants by untrained operators using three different lots of product to demonstrate the within run, between run and between operator precision. An identical panel of coded specimens, containing drugs at the concentration of \pm 50% and + 25% cut-off level, was labeled as a blind and tested at each site. The results are given below:

| Drug Cono | n | Site | e A | Site | e B | Site C | |
|-----------------------|--------------------|------------|-----------|----------|-------------|------------|--------------|
| Drug Conc. | per site | - | + | - | + | - | + |
| Negative | 90 | 90 | 0 | 90 | 0 | 90 | 0 |
| -50% Cut-off | 90 | 83 | 7 | 87 | 3 | 90 | 0 |
| -25% Cut-off | 90 | 67 | 23 | 75 | 15 | 80 | 10 |
| +25% Cut-off | 90 | 28 | 62 | 30 | 60 | 22 | 68 |
| +50% Cut-off | 90 | 1 | 89 | 0 | 90 | 2 | 88 |
| A study was conducted | at three physician | offices by | untrained | operator | 's usina th | nree diffe | rent lots of |

product to demonstrate the within run, between run and between operator precision. An identical panel of coded spectrations of the statistic drugs at concentrations of \pm 50% and \pm 25% cut-off level, was labeled, blinded and tested at each site. The results are given below:

AMPHETAMINE (AMP 300)

| Amphetamine | n nor oite | Site | e A | Site | e B | Site C | |
|---------------|------------|------|-----|------|-----|--------|----|
| conc. (ng/mL) | n per site | - | + | - | + | - | + |
| 0 | 15 | 15 | 0 | 15 | 0 | 15 | 0 |
| 150 | 15 | 15 | 0 | 15 | 0 | 15 | 0 |
| 225 | 15 | 9 | 6 | 14 | 1 | 11 | 4 |
| 375 | 15 | 1 | 14 | 3 | 12 | 0 | 15 |
| 450 | 15 | 0 | 15 | 0 | 15 | 0 | 15 |

BUPRENORPHINE (BUP)

| Buprenorphine | n per site | Site | еA | Site | еB | Site | еC |
|---------------|------------|------|----|------|----|------|----|
| conc. (ng/mL) | n per site | - | + | - | + | - | + |
| 0 | 15 | 15 | 0 | 15 | 0 | 15 | 0 |
| 5 | 15 | 15 | 0 | 15 | 0 | 15 | 0 |
| 7.5 | 15 | 8 | 7 | 10 | 5 | 9 | 6 |
| 12.5 | 15 | 0 | 15 | 1 | 14 | 0 | 15 |
| 15 | 15 | 0 | 15 | 0 | 15 | 0 | 15 |

COCAINE (COC 150)

| Benzoylecgonine | n nor oite | Sit | e A | Sit | e B | Site C | |
|-----------------|------------|-----|-----|-----|-----|--------|----|
| conc. (ng/mL) | n per site | - | + | - | + | - | + |
| 0 | 15 | 15 | 0 | 15 | 0 | 15 | 0 |
| 75 | 15 | 15 | 0 | 14 | 1 | 15 | 0 |
| 112 | 15 | 13 | 2 | 7 | 8 | 15 | 0 |
| 187 | 15 | 0 | 15 | 0 | 15 | 1 | 14 |
| 225 | 15 | 0 | 15 | 0 | 15 | 0 | 15 |

METHAMPHETAMINE (mAMP 500)

| Methamphetamine | n nor oite | Sit | еA | Sit | eВ | Site | еC |
|-----------------|------------|-----|----|-----|----|------|----|
| conc. (ng/mL) | n per site | - | + | - | + | - | + |
| 0 | 15 | 15 | 0 | 15 | 0 | 15 | 0 |
| 250 | 15 | 15 | 0 | 15 | 0 | 15 | 0 |
| 375 | 15 | 15 | 0 | 10 | 5 | 15 | 0 |
| 625 | 15 | 1 | 14 | 0 | 15 | 2 | 13 |
| 750 | 15 | 0 | 15 | 0 | 15 | 0 | 15 |

OXYCODONE (OXY)

| Oxycodone | n nor oite | Sit | еA | Sit | e B | Sit | еC |
|---------------|------------|-----|----|-----|-----|-----|----|
| conc. (ng/mL) | n per site | - | + | - | + | - | + |
| 0 | 15 | 15 | 0 | 15 | 0 | 15 | 0 |
| 50 | 15 | 15 | 0 | 15 | 0 | 15 | 0 |
| 75 | 15 | 14 | 1 | 13 | 2 | 11 | 4 |
| 125 | 15 | 1 | 14 | 0 | 15 | 0 | 15 |
| 150 | 15 | 0 | 15 | 0 | 15 | 0 | 15 |

PROPOXYPHENE (PPX)

| Propoxyphene | n nor oite | Site | еA | Sit | eВ | Site | еC |
|---------------|------------|------|----|-----|----|------|----|
| conc. (ng/mL) | n per site | - | + | - | + | - | + |
| 0 | 15 | 15 | 0 | 15 | 0 | 15 | 0 |
| 150 | 15 | 15 | 0 | 15 | 0 | 14 | 1 |
| 225 | 15 | 10 | 5 | 8 | 7 | 7 | 8 |
| 375 | 15 | 0 | 15 | 0 | 15 | 1 | 14 |
| 450 | 15 | 0 | 15 | 0 | 15 | 0 | 15 |

Analytical Sensitivity

| Drug | | AM | P 1.00 | ,000 AMP 300 | | | BAR | | | | BZO | | | |
|---|----------------------|----------|-------------------------|--------------|------|-------|-------|------|---------|---------------|----------------|----------------|----------|---------|
| concentration Cut-off Range | n | - | | + | - | | + | _ | | | + | | - | + |
| 0% Cut-off | 30 | 30 | (|) | 30 |) | 0 | | 3 | 0 | 0 | | 30 | 0 |
| -50% Cut-off | 30 | 30 | (|) | 30 |) | 0 | | 3 | 0 | 0 | | 30 | 0 |
| -25% Cut-off | 30 | 24 | (| 6 | 27 | ' | 3 | | 2 | 5 | 5 | | 25 | 5 |
| Cut-off | 30 | 17 | 1 | 3 | 13 | 3 | 17 | | 1 | 3 | 17 | 7 | 14 | 16 |
| +25% Cut-off | 30 | 5 | 2 | 5 | 4 | | 26 | i | | 7 | 23 | 3 | 10 | 20 |
| +50% Cut-off | 30 | 0 | 3 | 0 | 0 | | 30 |) | (|) | 30 |) | 0 | 30 |
| Drug | | C | DC 300 |) | C | coc | 150 | | | TH | IC | | M | TD |
| Concentration Cut-off Range | n | - | | + | - | | + | | | - | + | | - | + |
| 0% Cut-off | 30 | 30 | (| 0 | 30 |) | 0 | | 3 | 0 | 0 | | 30 | 0 |
| -50% Cut-off | 30 | 30 | (| 0 | 30 |) | 0 | | 3 | 0 | 0 | | 30 | 0 |
| -25% Cut-off | 30 | 25 | | 5 | 24 | ł | 6 | | 2 | 7 | 3 | | 20 | 10 |
| Cut-off | 30 | 19 | 1 | 1 | 14 | ł | 16 | ; | 1 | 4 | 16 | 3 | 19 | 11 |
| +25% Cut-off | 30 | 3 | 2 | 7 | 7 | | 23 | ; | | 6 | 24 | 1 | 7 | 23 |
| +50% Cut-off | 30 | 0 | 3 | 0 | 0 | | 30 |) | |) | 30 |) | 0 | 30 |
| Drug Concentration | n | mAl | MP 1,0 | 00 | m | AMF | o 500 | | | MD | MA | | M | OP |
| Cut-off Range | | - | | + | - | | + | | | - | + | | - | + |
| 0% Cut-off | 30 | 30 | | 0 | 30 |) | 0 | | | 0 | 0 | | 30 | 0 |
| -50% Cut-off | 30 | 30 | | 0 | 30 | - | 0 | | | 0 | 0 | | 30 | 0 |
| -25% Cut-off | 30 | 24 | | 6 | 23 | | 7 | | | 20 | 10 | | 27 | 3 |
| Cut-off | 30 | 18 | | 2 | 13 | | 17 | , | _ | 8 | 12 | | 17 | 13 |
| +25% Cut-off | 30 | 5 | | 25 | 8 | - | 22 | | | 0 | 20 | - | 10 | 20 |
| +50% Cut-off | 30 | 0 | | 30 | 0 | | 30 | _ | | 0 | 30 | | 0 | 30 |
| Drug | | | | | | | 1 | | | - | | | - | |
| Concentration Cut-off Range | n | - | PI + | - | OXY | + | - | PC | ۲; + | _ | - | -Χ + | - | TCA |
| 0% Cut-off | 30 | 30 | 0 | 30 | | 0 | 3 | 0 | 0 | - | 30 | 0 | 30 | C |
| -50% Cut-off | 30 | 30 | 0 | 30 | | 0 | 3 | - | 0 | - | 30 | 0 | 30 | 0 |
| -25% Cut-off | 30 | 25 | 5 | 30 | | 0 | 2 | - | 4 | - | 24 | 6 | 25 | 5 |
| Cut-off | 30 | 17 | 13 | 18 | | 12 | 1. | _ | 16 | ; | 17 | 13 | 18 | 1 |
| +25% Cut-off | 30 | 4 | 26 | 6 | | 24 | 6 | | 24 | | 7 | 23 | 5 | 2 |
| +50% Cut-off | 30 | 0 | 30 | 0 | | 30 | C | | 30 | | 0 | 30 | 0 | 3 |
| | [| Drug Co | oncentr | ation | | Γ. | | | BL | JP | | | | |
| | | Cut-c | off Rang | ge | | Ľ | n | | - | + | | | | |
| | | 0% | Cut-of | f | | 9 | 90 | 9 | 0 | 0 | | | | |
| | | -50% | 6 Cut-o | ff | | 9 | 90 | 9 | 0 | 0 | | | | |
| | | -25% | 6 Cut-o | ff | | 9 | 90 | 7 | 5 | 15 | | | | |
| | | С | ut-off | | | 9 | 90 | 6 | 0 | 30 | 1 | | | |
| | | +25% | 6 Cut-c | off | | 9 | 90 | 3 | 1 | 59 | 1 | | | |
| | | +50% | 6 Cut-c | off | | 9 | 90 | (|) | 90 | 1 | | | |
| following table lists Dne Step Multi-Dru | the conc Ig Scree | entratio | Analy ons of Card | comp | ound | ds (n | ng/ml |) th | at a | re de at 5 | etecte minu | ed as utes. | positive | e in ur |
| 0- | lumn 1A | | | | | | | | | C | olum | n 1B | | |
| 60 | | | | | | | | | | | | | | |
| PHETAMINE 1,000 (| | • | | | | MET | THAN | ЛРH | IET4 | | | 00 (m | AMP) | |

| Column 1A | | | | | | |
|-------------------------------------|---------|--|---------|--|--|--|
| AMPHETAMINE 1,000 (AMP) | 1 | METHAMPHETAMINE 1,000 (mAMP) | | | | |
| d-Amphetamine | 1,000 | d-Methamphetamine | 1,000 | | | |
| d,I-Amphetamine | 3,000 | p-Hydroxymethamphetamine | 30,000 | | | |
| I-Amphetamine | 50,000 | I-Methamphetamine | 8,000 | | | |
| 3,4-Methylenedioxyamphetamine (MDA) | 2,000 | 3,4-Methylenedioxymethamphetamine (MDMA) | 2,000 | | | |
| Phentermine | 3,000 | Mephentermine | 50,000 | | | |
| AMPHETAMINE 300 (AMP) | | METHAMPHETAMINE 500 (mAMP) | | | | |
| d-Amphetamine | 300 | d-Methamphetamine | 500 | | | |
| d,I-Amphetamine | 390 | d-Amphetamine | 50,000 | | | |
| I-Amphetamine | 50,000 | d,I-Amphetamine | 75,000 | | | |
| 3,4-Methylenedioxyamphetamine (MDA) | 1,560 | Chloroquine | 12,500 | | | |
| β-Phenylethylamine | 100,000 | 3,4-Methylenedioxymethamphetamine (MDMA) | 1,000 | | | |
| Phenylpropanolamine | 100,000 | p-Hydroxymethamphetamine | 15,000 | | | |
| Tyramine | 100,000 | Mephentermine | 25,000 | | | |
| p-Hydroxynorephedrine | 100,000 | (1R,2S)-(-)-Ephedrine | 50,000 | | | |
| (±)-Phenylpropanolamine | 100,000 | I-Phenylephrine | 100,000 | | | |
| p-Hydroxyamphetamine | 1,560 | β-Phenylethylamine | 75,000 | | | |
| d,I-Norephedrine | 100,000 | METHYLENEDIOXYMETHAMPHETAMINE (| MDMA) | | | |
| BARBITURATES (BAR) | | 3,4-Methylenedioxymethamphetamine (MDMA) | 500 | | | |
| Secobarbital | 300 | 3,4-Methylenedioxyamphetamine (MDA) | 3,000 | | | |
| Amobarbital | 300 | 3,4-Methylenedioxyethylamphetamine (MDEA) | 300 | | | |
| Alphenal | 150 | OPIATE 300 (MOP) | | | | |
| Aprobarbital | 200 | Morphine | 300 | | | |
| Butabarbital | 75 | Codeine | 300 | | | |
| Butalbital | 2,500 | Ethylmorphine | 6,250 | | | |
| Butethal | 100 | Hydrocodone | 50,000 | | | |
| Cyclopentobarbital | 600 | Hydromorphone | 3,125 | | | |
| Pentobarbital | 300 | Levorphanol | 1,500 | | | |
| Phenobarbital | 100 | 6-Monoacetylmorphine (6-MAM) | 400 | | | |
| BENZODIAZEPINES (BZO) | | Morphine 3-β-D-glucuronide | 1,000 | | | |
| Oxazepam | 300 | Norcodeine | 6,250 | | | |
| Alprazolam | 196 | Normorphine | 100,000 | | | |
| α-Hydroxyalprazolam | 1,262 | Oxycodone | 30,000 | | | |
| Bromazepam | 1,562 | Oxymorphone | 100,000 | | | |
| Chlordiazepoxide | 1,562 | Procaine | 150,000 | | | |
| Clobazam | 98 | Thebaine | 6,250 | | | |
| Clonazepam | 781 | OPIATE 2,000 (OPI) | | | | |
| Clorazepate | 195 | Morphine | 2,000 | | | |
| Delorazepam | 1,562 | Codeine | 2,000 | | | |
| Desalkylflurazepam | 390 | Ethylmorphine | 5,000 | | | |
| Diazepam | 195 | Hydrocodone | 12,500 | | | |
| Estazolam | 2,500 | Hydromorphone | 5,000 | | | |
| Flunitrazepam | 390 | Levorphanol | 75,000 | | | |
| (±) Lorazepam | 1,562 | 6-Monoacetylmorphine (6-MAM) | 5,000 | | | |

| Column 2A(Continued from Colu | ımn 1A) | Column 2B(Continued from C | olumn 1B) |
|-----------------------------------|---------|-----------------------------|-----------|
| RS-Lorazepam glucuronide | 156 | Morphine 3-β-D-glucuronide | 2,000 |
| Midazolam | 12,500 | Norcodeine | 12,500 |
| Nitrazepam | 98 | Normorphine | 50,000 |
| Norchlordiazepoxide | 195 | Oxycodone | 25,000 |
| Nordiazepam | 390 | Oxymorphone | 25,000 |
| Temazepam | 98 | Procaine | 150,000 |
| Triazolam | 2,500 | Thebaine | 100,000 |
| BUPRENORPHINE (BUP) | | OXYCODONE (OXY) | |
| Buprenorphine | 10 | Oxycodone | 100 |
| Norbuprenorphine | 20 | Naloxone | 37,500 |
| Buprenorphine 3-D-glucuronide | 15 | Naltrexone | 37,500 |
| Norbuprenorphine 3-D-glucuronide | 200 | Levorphanol | 50,000 |
| COCAINE 300 (COC) | | Hydrocodone | 6,250 |
| Benzoylecgonine | 300 | Hydromorphone | 50,000 |
| Cocaine | 780 | Oxymorphone | 200 |
| Cocaethylene | 12,500 | PHENCYCLIDINE (PCP) | |
| Ecgonine | 32,000 | Phencyclidine | 25 |
| COCAINE 150 (COC) | | 4-Hydroxyphencyclidine | 12,500 |
| Benzoylecgonine | 150 | PROPOXYPHENE (PPX) | |
| Cocaine | 400 | d-Propoxyphene | 300 |
| Cocaethylene | 6,250 | d-Norpropoxyphene | 300 |
| Ecgonine | 12,500 | TRICYCLIC ANTIDEPRESSANTS (| TCA) |
| Ecgonine methylester | 50,000 | Nortriptyline | 1,000 |
| MARIJUANA (THC) | | Nordoxepin | 1,000 |
| 11-nor-∆ ⁹ -THC-9 COOH | 50 | Trimipramine | 3,000 |
| Cannabinol | 20,000 | Amitriptyline | 1,500 |
| 11-nor-Δ ⁸ -THC-9 COOH | 30 | Promazine | 1,500 |
| ∆ ⁸ −THC | 15,000 | Desipramine | 200 |
| Δ ⁹ -THC | 15,000 | Imipramine | 400 |
| METHADONE (MTD) | | Clomipramine | 12,500 |
| Methadone | 300 | Doxepin | 2,000 |
| Doxylamine | 50,000 | Maprotiline | 2,000 |
| | | Promethazine | 25,000 |

Effect of Urinary Specific Gravity

Fifteen (15) urine samples of normal, high, and low specific gravity ranges (1.000-1.037) were spiked with drugs at 50% below and 50% above cut-off levels respectively. The **One Step Multi-Drug Screen Test Card with the Integrated** *i***Cup**[®] was tested in duplicate using fifteen drug-free urine and spiked urine samples. The results demonstrate that varying ranges of urinary specific gravity do not affect the test results.

Effect of Urinary pH

The pH of an aliquoted negative urine pool was adjusted to a pH range of 5 to 9 in 1 pH unit increments and spiked with drugs at 50% below and 50% above cut-off levels. The spiked, pHadjusted urine was tested with the One Step Multi-Drug Screen Test Card with the Integrated iCup[®]. The results demonstrate that varying ranges of pH do not interfere with the performance of the test.

Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds in either drugfree urine or drug positive urine containing, Amphetamine, Barbiturates, Buprenorphine, Benzodiazepines, Cocaine, Marijuana, Methadone, Methamphetamine, Methylenedioxymethamphetamine, Opiate, Oxycodone, Phencyclidine, Propoxyphene or Tricyclic Antidepressants. The following compounds show no cross-reactivity when tested with the One Step Multi-Drug Screen Test Card with the Integrated iCup[®] at a concentration of 100 µg/mL.

Non Cross Beasting Cor

| | Non Cross-Reactin | ig Compounds | |
|------------------------|------------------------|---------------------|---------------------|
| Acetaminophen | Creatinine | Ketoprofen | d-Pseudoephedrine |
| Acetophenetidin | Deoxycorticosterone | Labetalol | Quinacrine |
| N-Acetylprocainamide | Dextromethorphan | Loperamide | Quinine |
| Acetylsalicylic acid | Diclofenac | Meperidine | Quindine |
| Aminopyrine | Diflunisal | Meprobamate | Rantidine* |
| Amoxicillin | Digoxin | Methoxyphenamine | Salicylic acid |
| Ampicillin | Diphenhydramine | Methylphenidate | Serotonin |
| I-Ascorbic acid | I -Ψ-Ephedrine | Nalidixic acid | Sulfamethazine |
| Apomorphine | β-Estradiol | Naproxen | Sulindac |
| Aspartame | Estrone-3-sulfate | Niacinamide | Tetracycline |
| Atropine | Ethyl-p-aminobenzoate | Nifedipine | Tetrahydrocortisone |
| Benzilic acid | I (-)-Epinephrine | Norethindrone | 3-(β-D-glucuronide) |
| Benzoic acid | Erythromycin | Noscapine | Tetrahydrozoline |
| Benzphetamine* | Fenoprofen | d,I-Octopamine | Thiamine |
| Bilirubin | Furosemide | Oxalic acid | Thioridazine |
| d,I-Brompheniramine | Gentisic acid | Oxolinic acid | d,I-Tyrosine |
| Caffeine | Hemoglobin | Oxymetazoline | Tolbutamide |
| Cannabidol | Hydralazine | Papaverine | Triamterene |
| Chloralhydrate | Hydrochlorothiazide | Penicillin-G | Trifluoperazine |
| Chloramphenicol | Hydrocortisone | Pentazocine | Trimethoprim |
| Chlorothiazide | o-Hydroxyhippuric acid | Perphenazine | Tryptamine |
| d,I-Chloropheniramine | p-Hydroxytyramine | Phenelzine | d,I-Tryptophan |
| Chlorpromazine | Ibuprofen | Trans-2-phenylcyclo | Uric acid |
| Cholesterol | Iproniazid | propylamine | Verapamil |
| Clonidine | d,I-Isoproterenol | Prednisolone | Zomepirac |
| Cortisone | Isoxsuprine | Prednisone | |
| I-Cotinine | Ketamine | d,I-Propranolol | |
| *Parent compound only. | | | |

BIBLIOGRAPHY

Hawks RL, CN Chiang. Urine Testing for Drugs of Abuse. National Institute for Drug Abuse (NIDA), Research Monograph 73, 1986.

Research Monograph 73, 1986. Tietz NW. Textbook of Clinical Chemistry. W.B. Saunders Company. 1986; 1735. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 6th Ed. Biomedical Publ., Foster City, CA 2002. Stewart DJ, Inaba T, Lucassen M, Kalow W. *Clin. Pharmacol. Ther.* April 1979; 25 ed: 464, 264-8. Ambre J. J. Anal. Toxicol. 1985; 9:241. Winger, Gail, A Handbook of Drug and Alcohol Abuse, Third Edition, Oxford Press, 1992, page 146. FDA Guidance Document: Guidance for Premarket Submission for Kits for Screening Drugs of Abuse to be Lised by the Consumer 1997.

- be Used by the Consumer, 1997. Robert DeCresce. Drug Testing in the workplace, 1989 page 114. 8.

Printed in China

Manufactured for Alere Toxicology Services-Products Division Portsmouth, VA 23704 USA